• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Hospital Acquired MRSA pays no attention to vancomycin effectiveness

bys25qthea
November 7, 2012
in Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD/CDC. MRSA 

Key study points: 

  1. Hospital-acquired MRSA (HA-MRSA) infections have worse outcomes than community-acquired MRSA (CA-MRSA) infections regardless of their susceptibility to vancomycin.
  1. Worse outcomes from HA-MRSA infections may be due to unidentified virulence factors.

Primer: Methicillin-resistant Staphylococcus aureus (MRSA) has become an increasingly prevalent cause of infection worldwide. Methicillin resistance is conferred by the mecA gene, which is found on a mobile genetic element called staphylococcal chromosome cassette (SCCmec).  MecA encodes the peptidoglycan cross-linking protein PBP-2a to which most beta-lactams are unable to bind.  Six major mecA clones (SCCmec I-VI) have been identified.

HA-MRSA species generally contain the SCCmec type I, II, or III genes and are associated with higher rates of mortality and worse clinical outcomes while CA-MRSA generally possess SCCmec types IV and V and generally cause less severe infections.

To better understand why HA-MRSA causes more severe infections, this study’s authors examined how drug-susceptibility correlated with clinical outcome.  Specifically, the authors examined whether minimum inhibitory concentration (MIC) for vancomycin of different MRSA isolates correlated with treatment failure.

Of note, the clinical distinctions between CA and HA-MRSA have become less clear as patients are being colonized in one setting and developing infections in another; therefore this study defined HA-MRSA as isolates containing SCCmec type I,II or III and CA-MRSA isolates as containing types IV or V.

More background reading: 

RELATED REPORTS

Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy

Drinking characteristics in adolescence predict alcohol behaviors in early adulthood

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

1. Ganga R, Riederer K, Sharma M, et al. Role of SCCmec type in outcome of Staphylococcus aureus bacteremia in a single medical center. J Clin Microbiol 2009;47:590-5. 

2. Hota B, Lyles R, Rim J, et al. Predictors of clinical virulence in community-onset methicillin-resistant Staphylococcus aureus infections: the importance of USA300 and pneumonia. Clin Infect Dis 2011;53:757-65.

This [retrospective cohort] study by Chen et. al. pooled data from a prior study and examined records of all patients >15 years of age who were diagnosed with MRSA bacteremia, for a total of 291 patients in the study.  The SCCmec elements and MIC’s for vancomycin were identified for the different isolates.  The primary outcome for the study was treatment failure, which the authors defined as (1) all cause 30 day mortality; (2) persistent bacteremia after 7 days of treatment; or (3) recurrent MRSA bacteremia within 30 days of completing treatment with an appropriate anti-MRSA agent.

Patients were then categorized into groups: low vancomycin-MIC CA-MRSA (111), low-vancomycin-MIC HA-MRSA (127), and high vancomycin-MIC HA-MRSA (47). Low vancomycin-MIC was defined as </=1ug/ml, while high vancomycin-MIC was defined as >/=2ug/ml.

Analysis showed that HA-MRSA had a significantly higher treatment failure risk than CA-MRSA (aOR 1.98, 95% CI 1.131-3.496).  Additionally, the risk for treatment failure was higher for both low and high vancomycin-MIC HA-MRSA than for low vancomycin-MIC CA-MRSA patients (aOR 1.853 95% CI 1.0006 – 3.413 and aOR 2.393 95% CI 1.079-5.309 respectively).

In sum: This study suggests that the higher rates of treatment failure associated with HA-MRSA strains do not stem from vancomycin resistance.  The authors propose the existence of strain-specific virulence factors that affect clinical outcome.  The generalizability of this study requires clarification, however, as patient data was tracked from only a single center.  Additionally, retrospective cohort studies are subject to information bias.

The prospect of unidentified virulence factors affecting treatment outcome is compelling.  Further studies should attempt to identify these factors, and also to potentially seek targeted treatments to improve patient outcomes.

Click to read the study in Clinical Infectious Diseases  

By [AS] and [MP]

© 2012 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. DISCLAIMER: Posts are not medical advice and are not intended as such. Please see a healthcare professional if you seek medical advice.  

Previous Post

The ALTITUDE trial: Aliskiren increases the risk of adverse events and stroke without any cardiovascular or renal improvements in patients with Type 2 Diabetes

Next Post

[Physician Comment] Multiple sclerosis: Anti-cancer drug beats current first-line treatment in phase 3 trial

RelatedReports

Patient Basics: Thrombotic Stroke
Imaging and Intervention

Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy

March 24, 2023
Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment
Chronic Disease

Drinking characteristics in adolescence predict alcohol behaviors in early adulthood

March 24, 2023
Endocrinology

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

March 24, 2023
Cardiac mortality paradoxically lower during times of national cardiology conferences
Cardiology

72- and 36-hour fever prevention post-cardiac arrest equivalent in preventing mortality

March 24, 2023
Next Post

[Physician Comment] Multiple sclerosis: Anti-cancer drug beats current first-line treatment in phase 3 trial

[Physician Comment] Long-term pelvic muscle strength reduced after vaginal childbirth, forceps delivery

High degree of local and regional variation in health care spending among Medicare patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
  • Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options